Shares in Glaukos (NYSE:GKOS) rose today after the ophthalmological-focused medical device maker posted fourth quarter and full year 2018 earnings that topped expectations on Wall Street. The San Clemente, Calif.-based company posted profits of approximately $1.8 million, or 4¢ per share, on sales of approximately $54.1 million for the three months ended December 31, for bottom-line […]
Glaukos inks R&D deal for glaucoma therapy
Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy. Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration. According to the terms of the agreement, DWTI is slated […]
Glaukos touts Ph2 glaucoma trial for drug-eluting intraocular implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost […]
Glaukos touts iStent study with topical travoprost
Glaukos (NYSE:GKOS) touted data today from a 53-patient glaucoma study showing that its iStent device combined with topical travoprost reduced mean intraocular pressure by 35% after 18 months of follow-up. The company’s flagship device is designed to lessen IOP by restoring the natural outflow of aqueous humor through the conventional pathway in a patient’s eye. […]
Glaukos shares tumble despite Q1 beat
Shares in Glaukos (NYSE:GKOS) fell -10% today after the ophthalmic medtech company beat expectations on Wall Street with its 1st quarter results. The San Clemente, Calif.-based company posted profits of $878,000, or 2¢ per share, on sales of $35.9 million for the 3 months ended March 31, for bottom-line loss of -2% on sales growth of […]
Glaukos drops $6m on Dose Medical’s IOP sensor system
Glaukos (NYSE:GKOS) said today that it acquired Dose Medical‘s intraocular pressure sensor system assets for $5.5 million in cash, plus $9.5 million contingent upon development, clinical and regulatory milestones. The Dose Medical IOP sensor system includes a micro-invasive ocular implant that captures and stores a glaucoma patient’s short-interval IOP measurements. The system transmits data to […]
Teva Pharma CEO Vigodman steps down | Personnel Moves, February 7, 2017
Teva Pharmaceuticals (NYSE:TEVA) said this week that CEO Erez Vigodman has stepped down from their position at the head of the world’s biggest generic drugmaker. Vigodman’s exit from the company will take effect immediately, with board chair Yitzhak Peterburg taking on the interim role of chief exec. Israel-based Teva has seen shares plummet after a series of […]
Glaukos touts 3-year iStent study data
Glaukos (NYSE:GKOS) said today data from a 3-year study of its iStent Trabecular micro-bypass stent indicated that it, along with cataract surgery, lowered mean intraocular pressure 36% and reduced mean glaucoma medications by 86% 3 years post-surgery. The study reported a mean IP of 14.99 mmHg in 39 patients monitored after treatment for 3 years, compared […]
